Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
The inclusion and exclusion criteria for the patients who participated in lead-in Study 14362A will be transferred from the 14362A study and for the patients who did not participate in lead-in Study 14362A the inclusion/exclusion is separately listed below.~Inclusion Criteria:~1. The patient has a diagnosis of Dravet Syndrome supported by:~   1. onset of seizures in the first year of life~  2. history of fever-induced prolonged seizures as determined by the Investigator~      * these may include prolonged (approximately 15 minutes or longer) hemi-clonic seizures~  3. multiple seizure types which may include:~      * generalised tonic-clonic (required for inclusion)~     * clonic (required for inclusion)~     * myoclonic jerks/seizures~  4. history of normal development prior to seizure onset followed by development delay or regression after seizure onset~  5. abnormal EEG consistent with Dravet Syndrome~2. The patient is currently receiving a stable dose of clobazam of at least 0.5 mg/kg/day (maximum 20 mg/day) for at least 3 months~Other protocol-defined inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Clobazam (Type: EXPERIMENTAL): A maximum of 2.0 mg/kg/day (maximum 80 mg/day) twice daily (BID); clobazam oral suspension (2.5 mg/mL) or clobazam scored tablets (10 mg), orally

Based on this trial design, predict the completion outcome and termination type (if applicable).